Search Results for: 19

— Conference Call Scheduled for Thursday, March 2, 2017 at 4:30 p.m. EST — ROCKVILLE, Md., Feb. 21, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, intends to report operational highlights and financial results for […]

ROCKVILLE, Md., Feb. 3, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics to preserve the microbiome to protect and restore the health of patients, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 13, 2017, at 4:00 p.m.

— Enrollment in SYN-010 Pivotal Trial Will Be Open to All IBS-C Patients — ROCKVILLE, Md., Jan. 18, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today confirmed plans to initiate a Phase 2b/3 adaptive pivotal

— Presentation Planned for 9:30am (PT), Jan. 9, 2017 at Biotech Showcase in San Francisco — ROCKVILLE, Md., Jan. 5, 2017 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients, today announced positive topline data from its Phase 2b

– Granted Patent Provides Composition of Matter Protection for SYN-005 to at Least 2035 – ROCKVILLE, Md., Dec. 13, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that the United States Patent Office has granted U.S. Patent No. 9,512,204 which provides

ROCKVILLE, Md., Dec. 1, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that members of Synthetic Biologics’ executive leadership team will participate in two upcoming investor conferences: 2016 Jefferies Annual Microbiome Summit London, EnglandTuesday, December 13, 2016 Guggenheim Securities 4th Annual Boston Healthcare

ROCKVILLE, Md., Nov. 18, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced the closing of its previously announced underwritten public offering of 25,000,000 shares of its common stock and accompanying warrants to purchase 50,000,000 shares of its common stock at a

ROCKVILLE, Md., Nov. 15, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced the pricing of an underwritten public offering of 25,000,000 shares of its common stock and warrants to purchase 50,000,000 shares of its common stock at a price to the public

ROCKVILLE, Md., Nov. 14, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a late-stage clinical company developing therapeutics focused on the gut microbiome, today announced that it has commenced an underwritten public offering of shares of its common stock and warrants to purchase shares of its common stock.  The offering is subject to market

— Completed Enrollment of Phase 2b Proof-of-Concept Clinical Trial for the Prevention of C. difficile Infection (CDI), Antibiotic-Associated Diarrhea (AAD) and the Emergence of Antibiotic-Resistant Organisms — — Awarded Research Contract from Centers for Disease Control and Prevention to Determine SYN-004’s (ribaxamase) Ability to Prevent Antibiotic-Resistance in the Gut Microbiome — — Conference Call Today,